ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 034,14
0,52%
Dow Jones
38 644,05
-0,11%
DAX
18 694,45
1,14%
Brent Oil
79,525
-1,58%
Bitcoin
70 268,85
3,72%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) Actualités

CLDX

Celldex Therapeutics (CLDX)

Celldex Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CLDX
DateHeureSourceTitreSymboleSociété
02/06/202415h01GlobeNewswire Inc.Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024NASDAQ:CLDXCelldex Therapeutics Inc
31/05/202400h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
15/05/202414h01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
06/05/202422h01GlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
17/04/202414h01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
08/03/202413h00GlobeNewswire Inc.Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/03/202416h30GlobeNewswire Inc.Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/03/202416h10GlobeNewswire Inc.Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CLDXCelldex Therapeutics Inc
01/03/202422h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CLDXCelldex Therapeutics Inc
01/03/202403h14GlobeNewswire Inc.Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
28/02/202422h01GlobeNewswire Inc.Celldex Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
26/02/202413h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CLDXCelldex Therapeutics Inc
26/02/202413h01GlobeNewswire Inc.Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
24/02/202420h05GlobeNewswire Inc.Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
15/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
14/02/202422h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CLDXCelldex Therapeutics Inc
14/02/202418h52Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CLDXCelldex Therapeutics Inc
06/02/202422h01GlobeNewswire Inc.Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
05/02/202414h01GlobeNewswire Inc.Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024NASDAQ:CLDXCelldex Therapeutics Inc
27/11/202322h15GlobeNewswire Inc.Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
08/11/202305h15GlobeNewswire Inc.Celldex Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:CLDXCelldex Therapeutics Inc
06/11/202312h30GlobeNewswire Inc.Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
05/11/202321h00GlobeNewswire Inc.Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg BarzolvolimabNASDAQ:CLDXCelldex Therapeutics Inc
03/11/202321h01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CLDXCelldex Therapeutics Inc
02/11/202321h01GlobeNewswire Inc.Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
26/09/202313h01GlobeNewswire Inc.Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023NASDAQ:CLDXCelldex Therapeutics Inc
25/09/202314h31GlobeNewswire Inc.Celldex Therapeutics to Present at Cantor Global Healthcare ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
08/08/202322h01GlobeNewswire Inc.Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CLDX

Dernières Valeurs Consultées

USOTC
MCTYF
MicroPlanet Technology (GM)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés